Shares of Idexx Laboratories Inc. (NASDAQ:IDXX) hit a new 52-week high on Monday . The stock traded as high as $112.48 and last traded at $112.46, with a volume of 179,967 shares changing hands. The stock had previously closed at $110.15.

IDXX has been the topic of several research analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $120.00 price target (up previously from $92.00) on shares of Idexx Laboratories in a research report on Wednesday, August 3rd. Zacks Investment Research cut shares of Idexx Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Northcoast Research raised shares of Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Idexx Laboratories in a research report on Tuesday, August 2nd. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Idexx Laboratories presently has an average rating of “Buy” and an average price target of $105.20.

The firm has a market cap of $10.06 billion and a PE ratio of 50.95. The stock has a 50-day moving average price of $102.35 and a 200 day moving average price of $87.36.

Idexx Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 2nd. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.12. The business earned $467 million during the quarter, compared to analyst estimates of $444.83 million. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 EPS. Equities analysts expect that Idexx Laboratories Inc. will post $2.36 EPS for the current fiscal year.

In related news, Director Barry C. Johnson sold 9,924 shares of Idexx Laboratories stock in a transaction on Monday, August 15th. The shares were sold at an average price of $111.37, for a total value of $1,105,235.88. Following the transaction, the director now owns 13,484 shares in the company, valued at approximately $1,501,713.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Jonathan W. Ayers sold 60,000 shares of Idexx Laboratories stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $107.69, for a total transaction of $6,461,400.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Idexx Laboratories stock. Advisors Asset Management Inc. increased its stake in Idexx Laboratories Inc. (NASDAQ:IDXX) by 2.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,027 shares of the company’s stock after buying an additional 487 shares during the period. Advisors Asset Management Inc.’s holdings in Idexx Laboratories were worth $1,242,000 at the end of the most recent quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.